The U.S. government shutdown prevented FDA and NIH officials from attending the Drug Information Association's Clinical Trial Disclosure conference in Maryland, and FDA participants had to leave the Regulatory Affairs Professionals Society meeting in Boston, Jill Wechsler writes. The FDA stopped routine drug manufacturing facility inspections and clinical research locations, as well as accepting new regulatory filings that carry fees, she writes. Possible consequences include delays in carrying out programs and issuing documents, as well as missed review deadlines. Many FDA employees may have to be removed from the agendas of upcoming conferences.
Published in Brief: